This version of the registration was submitted prior to the Lobbying Transparency Act coming into force on May 4, 2020. Due to different information requirements at that time, the registration is presented in the following format.
Registration ID: 641354
Submitted by lobbyist on: May 15, 2017 01:15:05 PM
Accepted by Registrar on: May 15, 2017 02:19:27 PM
Designated Filer Information
| Lanman, Lydia |
| 3650 Danforth Avenue | |
|
Toronto, ON, M1N 2E8
|
587-337-4043 |
| Canada |
Organization Information
| Eli Lilly Canada Inc. |
| Eli Lilly is committed to providing answers that matter in medicine, life sciences and health care. As a leading inovation-driven pharmaceutical corporation, Lilly is developing a growing portfolio of products by applying the latest research from its own worldwide laboratories, by collaborating with eminent scientific organizations, by making use of the most up-to-date technological tools and by providing exceptional service to its customers. Headquartered in Indianapolis, Indiana, Lilly provides answers; through medicines and information; for some of the world's most urgent medical needs. Eli Lilly Canada, headquartered in Toronto, Ontario, employs more than 500 people across the country. Additional information about Eli Lilly Canada can be found at www.lilly.ca. |
| 3650 Danforth Avenue | |
|
Toronto, ON, M1N 2E8
|
587-337-4043 |
| Canada |
Relevant Affiliates
Government or Government Agency Funding
Other Controlling or Directing Interests
Active Registration Period
| May 15, 2017 | |
| November 11, 2017 |
Organization's In-House Lobbyists
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical pricing, pan-Canadian Pharmaceutical Alliance (pCPA)initiatives, public drug plan design, and health system design.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Clark, Christy | Premier | May 15, 2017 |
| Minister | Dix, Adrian | Minister of Health | August 8, 2017 |
| Minister | Horgan, John | Premier | August 8, 2017 |
| Minister | Lake, Terry | Minister of Health | May 15, 2017 |
| Public Agency | Health | May 15, 2017 |
Intellectual Property
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to the importance of pharmaceutical intellectual property protection and patent utility.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Barnett, Donna | Minister of State for Rural Economic Development | May 15, 2017 |
| Minister | Clark, Christy | Premier | May 15, 2017 |
| Minister | Glumac, Rick | Parliamentary Secretary for Technology | August 8, 2017 |
| Minister | Horgan, John | Premier | August 8, 2017 |
| Minister | Lake, Terry | Minister of Health | May 15, 2017 |
| Minister | Ralston, Bruce | Minister of Jobs, Trade and Technology | August 8, 2017 |
| Minister | Virk, Amrik | Minister of Technology, Innovation and Citizens' Services | May 15, 2017 |
| Minister | Wat, Teresa | Minister of International Trade | May 15, 2017 |
| Minister | Wilkinson, Andrew | Minister of Advanced Education | May 15, 2017 |
Science and Technology
Development, establishment, amendment or termination of any program, policy or decision
Policy discussions related to pharmaceutical innovation, research and development, and Lilly's approach to global partnering and investment.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Minister | Clark, Christy | Premier | May 15, 2017 |
| Minister | Dix, Adrian | Minister of Health | August 8, 2017 |
| Minister | Glumac, Rick | Parliamentary Secretary for Technology | August 8, 2017 |
| Minister | Horgan, John | Premier | August 8, 2017 |
| Minister | Lake, Terry | Minister of Health | May 15, 2017 |
| Minister | Virk, Amrik | Minister of Technology, Innovation and Citizens' Services | May 15, 2017 |
|
|||||
|
|
BC Public Office Background
Lobbying Activities
Health
Development, establishment, amendment or termination of any program, policy or decision
Discussions related to Eli Lilly's products in the following therapeutic areas for the purpose of maintaining and/or obtaining public reimbursement: diabetes, depression, chronic pain, psoriasis, rheumatoid arthritis, pediatric growth hormone deficiency, lung cancer, colorectal cancer, gastric cancer, soft tissue sarcoma, breast cancer.
Target Contacts
| Target Type | Name | Title or Constituency | Date Added |
|---|---|---|---|
| Public Agency | Fraser Health Authority | May 15, 2017 | |
| Public Agency | Health | May 15, 2017 | |
| Public Agency | Interior Health Authority | May 15, 2017 | |
| Public Agency | Providence Health Care Society | May 15, 2017 | |
| Public Agency | Provincial Health Services Authority | May 15, 2017 | |
| Public Agency | Vancouver Coastal Health Authority | May 15, 2017 | |
| Public Agency | Vancouver Island Health Authority | May 15, 2017 |